Oral, acute LD50 is 1100 mg/kg in dog. Symptoms of overdose include primarily sleepiness and mild dysphoria.
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. |
| Magnesium sulfate | The therapeutic efficacy of Nalbuphine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Nalbuphine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. |
| Orphenadrine | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. |
| Pramipexole | Nalbuphine may increase the sedative activities of Pramipexole. |
| Ropinirole | Nalbuphine may increase the sedative activities of Ropinirole. |
| Rotigotine | Nalbuphine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Nalbuphine. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Nalbuphine is combined with Sodium oxybate. |
| Suvorexant | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | The therapeutic efficacy of Tapentadol can be decreased when used in combination with Nalbuphine. |
| Thalidomide | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Nalbuphine is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Nalbuphine is combined with Desmopressin. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Nalbuphine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Nalbuphine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Nalbuphine. |
| Methylnaltrexone | Nalbuphine may increase the opioid antagonism activities of Methylnaltrexone. |
| Naloxegol | Nalbuphine may increase the opioid antagonism activities of Naloxegol. |
| Mirtazapine | Nalbuphine may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Nalbuphine. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Alaproclate. |
| Ethanol | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine. |
| Phentermine | Phentermine may increase the analgesic activities of Nalbuphine. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Nalbuphine. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Nalbuphine. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Nalbuphine. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Nalbuphine. |
| MMDA | MMDA may increase the analgesic activities of Nalbuphine. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Nalbuphine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Nalbuphine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Nalbuphine. |
| Tenamfetamine | Tenamfetamine may increase the analgesic activities of Nalbuphine. |
| Chlorphentermine | Chlorphentermine may increase the analgesic activities of Nalbuphine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may increase the analgesic activities of Nalbuphine. |
| Dextroamphetamine | Dextroamphetamine may increase the analgesic activities of Nalbuphine. |
| Metamfetamine | Metamfetamine may increase the analgesic activities of Nalbuphine. |
| Iofetamine I-123 | Iofetamine I-123 may increase the analgesic activities of Nalbuphine. |
| Ritobegron | Ritobegron may increase the analgesic activities of Nalbuphine. |
| Mephedrone | Mephedrone may increase the analgesic activities of Nalbuphine. |
| Methoxyphenamine | Methoxyphenamine may increase the analgesic activities of Nalbuphine. |
| Gepefrine | Gepefrine may increase the analgesic activities of Nalbuphine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Nalbuphine. |
| Amphetamine | Amphetamine may increase the analgesic activities of Nalbuphine. |
| Phendimetrazine | Phendimetrazine may increase the analgesic activities of Nalbuphine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Nalbuphine. |
| Pentolinium | The risk or severity of adverse effects can be increased when Pentolinium is combined with Nalbuphine. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Trimethaphan is combined with Nalbuphine. |
| Chloroprocaine | The risk or severity of CNS depression can be increased when Nalbuphine is combined with Chloroprocaine. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with Nalbuphine. |
| Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione | The risk or severity of adverse effects can be increased when Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione is combined with Nalbuphine. |
| Agmatine | The risk or severity of adverse effects can be increased when Agmatine is combined with Nalbuphine. |
| Promazine | The risk or severity of adverse effects can be increased when Promazine is combined with Nalbuphine. |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nalbuphine. |
| Triflupromazine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Nalbuphine. |
| Promethazine | The risk or severity of adverse effects can be increased when Promethazine is combined with Nalbuphine. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Nalbuphine. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Nalbuphine. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Nalbuphine. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Nalbuphine. |
| Ipratropium | The risk or severity of adverse effects can be increased when Ipratropium is combined with Nalbuphine. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Nalbuphine. |
| Terfenadine | The risk or severity of adverse effects can be increased when Terfenadine is combined with Nalbuphine. |
| Buclizine | The risk or severity of adverse effects can be increased when Buclizine is combined with Nalbuphine. |
| Trihexyphenidyl | The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Nalbuphine. |
| Oxyphencyclimine | The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Nalbuphine. |
| Procyclidine | The risk or severity of adverse effects can be increased when Procyclidine is combined with Nalbuphine. |
| Profenamine | The risk or severity of adverse effects can be increased when Profenamine is combined with Nalbuphine. |
| Hyoscyamine | The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Nalbuphine. |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Nalbuphine. |
| Methscopolamine bromide | The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Nalbuphine. |
| Darifenacin | The risk or severity of adverse effects can be increased when Darifenacin is combined with Nalbuphine. |